Of practical relevance for cancer treatment, it also significantly diminished the efficacy of the IL-2/doxorubicin chemo-immunotherapy treatment regimen and substantially, yet not significantly, aggravated the effects of the anti-PD-L1 treatment. This evidence concerns the gene CD274 and cancer.